Literature DB >> 3477297

Analyses of phenotype and genotype in acute lymphoblastic leukemias at first presentation and in relapse.

A Raghavachar1, E Thiel, C R Bartram.   

Abstract

As a clue to the cellular origin of leukemic populations in relapse we analyzed 11 cases of acute lymphoblastic leukemia (ALL) by immunological and molecular genetic approaches. Blast cells obtained from both initial diagnosis and relapse were immunophenotyped using a variety of monoclonal antibodies; simultaneously we hybridized Southern blots of respective cell samples to immunoglobulin (Ig) heavy and light chain as well as to T-cell receptor beta-chain (T beta) sequences. While similar phenotypes were observed in both states of nine cases, comparison of Ig gene rearrangements revealed clonal variations, ie, appearance of an evoluted or novel leukemic cell clone in relapse beside identical leukemic populations in both states. One pre-T (ALL) patient, presenting with germline configuration of T beta gene sequences at diagnosis, exhibited a rearrangement of T beta gene sequences in recurrent disease. Another patient displayed T-ALL phenotype and T beta gene rearrangement at diagnosis but relapsed with a very immature phenotype and germline configuration for T beta sequences. Our results emphasize the value of molecular analyses in order to unravel the nature of leukemic relapse.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3477297

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

1.  The study of minimal residual disease in acute lymphoblastic leukaemia.

Authors:  C J Knechtli; N J Goulden; K Langlands; M N Potter
Journal:  Clin Mol Pathol       Date:  1995-04

Review 2.  Treatment strategies in acute myeloid leukemia (AML). B. Second line treatment.

Authors:  W Hiddemann; T Büchner
Journal:  Blut       Date:  1990-03

3.  Determining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia.

Authors:  Michael J Brisco; Sue Latham; Rosemary Sutton; Elizabeth Hughes; Vicki Wilczek; Katrina van Zanten; Bradley Budgen; Anita Y Bahar; Maria Malec; Pamela J Sykes; Bryone J Kuss; Keith Waters; Nicola C Venn; Jodie E Giles; Michelle Haber; Murray D Norris; Glenn M Marshall; Alexander A Morley
Journal:  J Mol Diagn       Date:  2009-03-26       Impact factor: 5.568

4.  CD7 aberrant expression led to a lineage switch at relapsed childhood acute pre-B lymphoblastic leukemia.

Authors:  Vahid Fallah Azad; Amir Abbas Hedayati Asl; Maryam Tashvighi; Naghmeh Niktoreh Mofrad; Mansoureh Haghighi; Azim Mehrvar
Journal:  Med Mol Morphol       Date:  2015-08-05       Impact factor: 2.309

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.